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Abstract Viruses manipulate host cells to enhance their replication, and the identification of
cellular factors targeted by viruses has led to key insights into both viral pathogenesis and cell
biology. In this study, we develop an HIV reporter virus (HIV-AFMACS) displaying a streptavidin-
binding affinity tag at the surface of infected cells, allowing facile one-step selection with
streptavidin-conjugated magnetic beads. We use this system to obtain pure populations of HIV-
infected primary human CD4+ T cells for detailed proteomic analysis, and quantitate approximately
9000 proteins across multiple donors on a dynamic background of T cell activation. Amongst 650
HIV-dependent changes (q < 0.05), we describe novel Vif-dependent targets FMR1 and DPH7, and
192 proteins not identified and/or regulated in T cell lines, such as ARID5A and PTPN22. We
therefore provide a high-coverage functional proteomic atlas of HIV infection, and a mechanistic
account of host factors subverted by the virus in its natural target cell.
DOI: https://doi.org/10.7554/eLife.41431.001
Introduction
Remodelling of the host proteome during viral infection may reflect direct effects of viral proteins,
secondary effects or cytopathicity accompanying viral replication, or host countermeasures such as
the interferon (IFN) response. By defining time-dependent changes in protein levels in infected cells,
and correlating temporal profiles of cellular and viral proteins, we have shown that it is possible to
differentiate these phenomena, and identify direct cellular targets of human cytomegalovirus
(HCMV) and HIV (Greenwood et al., 2016; Matheson et al., 2015; Weekes et al., 2014). To enable
time course analysis and minimise confounding effects from uninfected bystander cells, pure popula-
tions of synchronously infected cells must be sampled sequentially as they progress through a single
round of viral replication. In the case of HIV, we previously satisfied these conditions by spinoculating
the highly permissive CEM-T4 lymphoblastoid T cell line (Foley et al., 1965; O’Doherty et al.,
2000; Popovic et al., 1984) with Env-deficient NL4-3-DEnv-EGFP virus (Zhang et al., 2004) at a
high multiplicity of infection (MOI) (Greenwood et al., 2016).
The utility of cancer cell line models (such as CEM-T4) is, however, limited by the extent to which
they retain the characteristics of the primary cells from which they were derived, and cancer-specific
and in vitro culture-dependent reprogramming are well described (Gillet et al., 2013). For example,
the HIV accessory proteins Vif, Nef and Vpu are required for viral replication in primary T cells, but
not in many T cell lines (Neil et al., 2008; Rosa et al., 2015; Sheehy et al., 2002; Usami et al.,
2015), and HIV is restricted by type I IFN in primary T cells, but not CEM-derived T cells
(Goujon et al., 2013). In addition, whilst ensuring a high % infection, dysregulation of the cellular
proteome at high MOIs may not be indicative of protein changes when a single transcriptionally
active provirus is present per cell.
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In this study, we therefore sought to apply our temporal proteomic approach to HIV infection of
primary human CD4+ T lymphocytes, the principle cell type infected in vivo, at an MOI  1. To this
end, we have developed an HIV reporter virus encoding a cell surface streptavidin-binding affinity
tag, allowing antibody-free magnetic cell sorting of infected cells (AFMACS) (Matheson et al.,
2014) (Figure 1A). This system allows rapid, scalable, affinity purification of HIV-infected cells from
mixed cultures, bypassing the need for high MOIs or fluorescence-activated cell sorting (FACS). We
use this system to generate a detailed atlas of cellular protein dynamics in HIV-infected primary
human CD4+ T cells, show how this resource can be used to identify novel cellular proteins regu-
lated by HIV, and assign causality to individual HIV accessory proteins.
Results
Design and construction of the HIV-AFMACS reporter virus
AFMACS-based magnetic selection requires the high-affinity 38 amino acid streptavidin-binding
peptide (SBP) (Keefe et al., 2001) to be displayed at the cell surface by fusion to the N-terminus of
the truncated Low-affinity Nerve Growth Factor Receptor (SBP-DLNGFR) (Ruggieri et al., 1997).
Cells expressing this marker may be selected directly with streptavidin-conjugated magnetic beads,
washed to remove unbound cells, then released by incubation with the naturally occurring vitamin
biotin (Matheson et al., 2014). To engineer a single round HIV reporter virus encoding SBP-D
LNGFR, we considered three settings in the proviral construct: fused to the endogenous Env signal
peptide (as a direct replacement for Env); or as an additional cistron, downstream of nef and either a
P2A peptide or IRES. We used Env-deficient pNL4-3-DEnv-EGFP (HIV-1) as a backbone and, since
increased size of lentiviral genome is known to reduce packaging efficiency (Kumar et al., 2001),
tested each approach in constructs from which EGFP was removed and/or the 3’ long terminal
repeat (LTR) truncated. Further details relating to construct design are described in the Materials
and methods and Supplementary file 1.
For initial screening, VSVg-pseudotyped viruses were made in HEK-293T cells under standard
conditions, and used to spinoculate CEM-T4 T cells (CEM-T4s). Infected cells were identified by
expression of EGFP and/or cell surface LNGFR, combined with Nef/Vpu-mediated downregulation
of CD4 (Guy et al., 1987; Willey et al., 1992). Whilst infection is not truly ‘productive’ (because Env
is deleted), Gag alone is sufficient for assembly and release of virions (Gheysen et al., 1989), and
other structural and non-structural viral proteins are expressed in accordance with full length viral
infection (Greenwood et al., 2016).
As expected, all viruses tested expressed SBP-DLNGFR at the cell surface of infected cells (Fig-
ure 1—figure supplement 1A), but the larger constructs resulted in lower infectious viral titres (Fig-
ure 1—figure supplement 1A–B). We therefore selected pNL4-3-DEnv-SBP-DLNGFR, pNL4-3-D
ENV-Nef-P2A-SBP-DLNGFR and pNL4-3-DEnv-Nef-IRES-SBP-DLNGFR-D3 for further evaluation (Fig-
ure 1—figure supplement 2). Viruses generated from these constructs expressed high levels of
SBP-DLNGFR 48 hr post-infection, and depleted CD4 and tetherin to a similar extent. However, only
the pNL4-3-DENV-Nef-P2A-SBP-DLNGFR virus (Figure 1B) expressed high levels of LNGFR 24 hr
post-infection in both CEM-T4s (Figure 1—figure supplement 2) and primary human CD4+ T cells
(Figure 1C). This is consistent with Nef-P2A-SBP-DLNGFR expression from completely spliced tran-
scripts early in HIV infection (Klotman et al., 1991), with the P2A peptide ensuring that translation
of Nef and SBP-DLNGFR follow similar kinetics.
Since analysis of cells at early as well as late time points is essential for the generation of time
course data, we focussed on pNL4-3-DEnv-Nef-P2A-SBP-DLNGFR (now termed HIV-AFMACS). To
confirm that HIV-AFMACS virus could be used for cell selection (Figure 1A), infected primary T cells
were captured by streptavidin-conjugated magnetic beads, released by incubation with excess bio-
tin, then analysed by flow cytometry. Compared with unselected cells (input) or cells released during
washing (flow-through), selected cells were markedly enriched for SBP-DLNGFR expression and CD4
downregulation (Figure 1D). In fact, from mixed populations containing approximately 20–40%
infected cells, purities of  90% were routinely achieved by AFMACS of both CEM-T4s and primary
human CD4+ T cells, with  10% infected cells lost in the flow-through (Figure 1E). The full HIV-
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Figure 1. Antibody-free magnetic selection of HIV-infected primary T cells. (A) Workflow for AFMACS-based magnetic selection of HIV-infected primary
T cells. (B) Schematic of HIV-AFMACS provirus (pNL4-3-DEnv-Nef-P2A-SBP-DLNGFR). For simplicity, reading frames are drawn to match the HXB2 HIV-1
reference genome. Length is indicated in base pairs (bp). The complete sequence is available in Supplementary file 1. Nef-hu, codon-optimised Nef;
Figure 1 continued on next page
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AFMACS sequence is available from GenBank (accession: MK435310) and in Supplementary file 1,
and the proviral construct will be made available to the community via the National Institutes of
Health (NIH) AIDS Reagent Program.
Time-dependent proteomic remodelling during HIV infection of primary
T cells
To gain a comprehensive, unbiased overview of viral and cellular protein dynamics during HIV-infec-
tion of its natural target cell, we used the HIV-AFMACS virus to spinoculate activated, primary
human CD4+ T cells, sorted infected (SBP-DLNGFR positive) and uninfected (SBP-DLNGFR negative)
cells by AFMACS 24 hr and 48 hr post-infection, and analysed whole cell lysates using tandem mass
tag (TMT)-based quantitative proteomics (Figure 2A–B and Figure 2—figure supplement 1A)
(Greenwood et al., 2016; Weekes et al., 2014). Interpretation of HIV-dependent proteomic remod-
elling in primary T cells is complicated by concurrent changes in relative protein abundance resulting
from T cell activation (Geiger et al., 2016). We therefore exploited multiplex TMT labelling to mea-
sure parallel protein abundances in resting and activated (uninfected) T cells from the same donor,
as well as control (mock-infected) T cells obtained at each time point.
In total, we quantitated 9070 cellular proteins across 10 different conditions. As previously
reported (Geiger et al., 2016), T cell activation itself caused extensive proteomic remodelling, with
relative abundances of 2677/9070 (29%) proteins changing by > 2 fold in activated vs resting cells
(Figure 2—figure supplement 2). All data from infected and uninfected cells have been made avail-
able via ProteomeXchange with identifier PXD012263, and are summarised in an interactive
spreadsheet allowing generation of temporal profiles for any quantitated proteins of interest (Fig-
ure 2—source data 1). For example, the restriction factor tetherin (targeted by HIV-1 Vpu
[Neil et al., 2008]) is upregulated by T cell activation, then progressively depleted in HIV-infected
(red, SBP-DLNGFR positive) but not uninfected (blue, SBP-DLNGFR negative) cells (Figure 2C, left
panel). Conversely, the restriction factor SAMHD1 (targeted by some HIV-2/SIV Vpx and Vpr var-
iants, but not HIV-1 [Hrecka et al., 2011; Laguette et al., 2011; Lim et al., 2012]) is depleted by T
cell activation, independent of HIV infection (Figure 2C, right panel). In these graphical representa-
tions, relative protein abundances for each condition are depicted by bars, and ratios of protein
abundances in paired experimental/control cells from each condition/time point are depicted by
lines (grey, resting/activated; red, SBP-DLNGFR positive, infected; blue, SBP-DLNGFR negative,
uninfected).
Aside from tetherin, levels of many other reported Vpu (CD4, SNAT1) (Matheson et al., 2015;
Willey et al., 1992), Nef (CD4, SERINC5) (Guy et al., 1987; Rosa et al., 2015; Usami et al., 2015),
Vif (APOBEC3 and PPP2R5 families) (Greenwood et al., 2016; Sheehy et al., 2002) and Vpr (UNG,
HLTF, ZGPAT, VPRBP, MUS81, EME1, MCM10, TET2) (Hrecka et al., 2016; Lahouassa et al., 2016;
Lapek et al., 2017; Lv et al., 2018; Maudet et al., 2013; Romani et al., 2015;
Schro¨felbauer et al., 2005; Zhou et al., 2016) substrates were all reduced by HIV infection in pri-
mary T cells (Figure 2D, and Figure 2—figure supplement 1B). Conversely, and consistent with our
previous observations in CEM-T4s, APOBEC3B and SERINC1 were not depleted (Figure 2—figure
supplement 1B) (Greenwood et al., 2016; Matheson et al., 2015). In the absence of donor haplo-
typing, polymorphisms at the MHC-I locus make routine proteomic quantification problematic.
Figure 1 continued
RRE, Rev response element; SP, signal peptide. (C) Expression of cell surface SBP-DLNGFR and CD4 on primary T cells 24 or 48 hr post-infection with
HIV-AFMACS. Cells were stained with anti-LNGFR and anti-CD4 antibodies at the indicated time points and analysed by flow cytometry. (D–E)
Magnetic sorting of HIV-infected (red, LNGFR+, CD4 low) and uninfected (blue, LNGFR-, CD4 high) cells. Cells were separated using AFMACS 48 hr
post-infection with HIV-AFMACS and analysed as in (C). Representative (D) and summary (E) data from six independent experiments in CEM-T4s
(triangles) and primary T cells (circles) are shown, with means and 95% confidence intervals (CIs).
DOI: https://doi.org/10.7554/eLife.41431.002
The following figure supplements are available for figure 1:
Figure supplement 1. Initial screen of SBP-DLNGFR-expressing HIV viruses.
DOI: https://doi.org/10.7554/eLife.41431.003
Figure supplement 2. Time course evaluation of selected SBP-DLNGFR-expressing HIV viruses.
DOI: https://doi.org/10.7554/eLife.41431.004
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Figure 2. Temporal proteomic analysis of HIV infection in primary T cells. (A) Overview of time course proteomic experiment. Control (pale grey,
resting/activated/mock) and experimental (dark grey, resting/activated; red, LNGFR+, HIV-infected, selected; blue, LNGFR-, uninfected, flow-through)
cells are indicated for each condition/time point. (B) Magnetic sorting of HIV-infected (red, LNGFR+, selected) cells used for (A). Corresponding
uninfected (LNGFR-, flow-through) cells are shown in Figure 2—figure supplement 1A. Cells were separated using AFMACS at the indicated time
Figure 2 continued on next page
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Nonetheless, our data are consistent with depletion of HLA-A and HLA-B, but not HLA-C (Figure 2—
figure supplement 1B), as previously reported for Nef/Vpu variants from NL4-3 HIV (Apps et al.,
2016; Cohen et al., 1999; Schwartz et al., 1996).
Together with cellular proteins, we identified gene products from seven viral open reading frames
(ORFs; Figure 2—figure supplement 1C). As expected (Karn and Stoltzfus, 2012), viral regulatory
and accessory proteins expressed from fully spliced, Rev-independent transcripts (Tat, Rev, Nef-P2A
and SBP-DLNGFR) were expressed early in infection, peaking at 24 hr. Conversely, viral structural
proteins expressed from unspliced, Rev-dependent transcripts (Gag and Gagpol) were expressed
late in infection, increasing progressively from 24 to 48 hr. Viral accessory proteins expressed from
partially spliced transcripts were either not detected (Vpr and Vpu) or incompletely quantitated (Vif).
Proteins and pathways regulated by HIV in primary T cells from
multiple donors
Inter-individual variability is known to affect gene expression during T cell activation (Ye et al.,
2014). Accordingly, to identify reproducible HIV targets, we analysed primary human CD4+ T cells
from three further donors. In each case, mock-infected cells were compared with HIV-infected cells
selected using AFMACS 48 hr post-infection (Figure 3A–B and Figure 3—figure supplement 1A).
Aside from APOBEC3 proteins, we recently discovered the PPP2R5A-E (B56) family of PP2A phos-
phatase regulatory subunits to be degraded by diverse Vif variants, spanning primate and ruminant
lentiviruses (Greenwood et al., 2016). To formally document Vif-dependent changes in primary T
cells, both wildtype (WT) and Vif-deficient (DVif) viruses were therefore included. Whilst some donor-
dependent differences were apparent, most sample-sample variability was accounted for by HIV
infection (Figure 3—figure supplement 1B), and all accessory protein substrates from Figure 2C–D
and Figure 2—figure supplement 1B were significantly depleted by WT HIV (Figure 3C, left panel).
In total, we quantitated 8789 cellular proteins across nine different conditions, of which 650 were
significantly regulated by HIV infection (q < 0.05) and are summarised in an interactive filter table
(Figure 3—source data 1).
Compared with a previous, similar experiment using CEM-T4s (Greenwood et al., 2016), we
observed greater variability in protein abundances between replicates (Figure 3—figure supple-
ment 2A), but a high degree of correlation in HIV-dependent changes between cell types (Fig-
ure 3—figure supplement 2B). As well as ‘canonical’ accessory protein targets, we have recently
discovered that most protein-level changes in HIV-infected CEM-T4s may be explained by primary
and secondary effects of Vpr, including degradation of at least 34 additional substrates
(Greenwood et al., 2019). These changes were recapitulated in primary T cells (Figure 3C, middle
Figure 2 continued
points post-infection with HIV-AFMACS, stained with anti-LNGFR and anti-CD4 antibodies and analysed by flow cytometry. Mock-infected cells are
shown in grey. (C) Expression profiles of illustrative restriction factors regulated by T cell activation and HIV infection (tetherin) or T cell activation alone
(SAMHD1) in cells from (A–B). Relative abundances (bars, fraction of maximum) and log2(ratio)s of abundances (lines) in experimental (Expt):control
(Ctrl) cells are shown for each condition/time point and coloured as in (A) (summarised in the key). (D) Expression profiles of illustrative accessory
protein targets (CD4, Nef/Vpu; SERINC5, Nef; SNAT1, Vpu; APOBEC3G, Vif; PPP2R5D, Vif; UNG, Vpr) in cells from (A–B). Axes, scales and colours are
as in (C). Expression profiles of other accessory protein targets are shown in Figure 2—figure supplement 1B. (E) Patterns of temporal regulation of
Vpr vs other accessory protein (Vif/Nef/Vpu) targets in cells from (A–B). Log2(ratio)s of abundances in experimental (Expt):control (Ctrl) cells are shown
for 45 accessory protein targets (as in Figure 2—figure supplement 3A). Colours are as in (C), and average profiles (mean, black lozenges/dotted
lines) are highlighted for each group of targets.
DOI: https://doi.org/10.7554/eLife.41431.005
The following source data and figure supplements are available for figure 2:
Source data 1. Functional proteomic atlas of HIV-infection in primary human CD4+ T cells.
DOI: https://doi.org/10.7554/eLife.41431.006
Figure supplement 1. Additional controls for time course proteomic experiment.
DOI: https://doi.org/10.7554/eLife.41431.007
Figure supplement 2. Comparison with T cell activation-dependent changes in Geiger et al. (2016).
DOI: https://doi.org/10.7554/eLife.41431.008
Figure supplement 3. Temporal clustering of HIV accessory protein targets.
DOI: https://doi.org/10.7554/eLife.41431.009
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Figure 3. Proteins regulated by HIV in primary T cells. (A) Overview of single time point proteomic experiment. HIV-infected (LNGFR+) primary T cells
were isolated using AFMACS 48 hr post-infection with WT (red) or DVif (blue) HIV-AFMACS. (B) AFMACS-based enrichment of WT (red circles) and DVif
(blue triangles) HIV-infected (LNGFR+) cells used for (A), with means and 95% CIs. Corresponding cells pre-selection are included for each donor/virus
(WT, grey circles; DVif, grey triangles). Cells were stained with anti-LNGFR and anti-CD4 antibodies and analysed by flow cytometry, with representative
Figure 3 continued on next page
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panel), with 33 newly described Vpr substrates quantitated, and 32 decreased in abundance. Several
other cell surface proteins reported to be downregulated by Nef and/or Vpu were also depleted,
but the magnitude of effect was typically modest, and many were unchanged (Figure 3—figure sup-
plement 3A, left panel). Likewise, we did not see evidence of HIV/Vif-dependent transcriptional reg-
ulation of RUNX1 target gene products such as T-bet/TBX21 (Figure 3—figure supplement 3A,
middle panel) (Kim et al., 2013). Nonetheless, taken together, known accessory protein-dependent
changes, characterised in transformed T cell lines, are able to account for 297/650 (46%) of proteins
regulated by HIV in primary T cells (Figure 3—figure supplement 3B), including 175/299 (59%) of
proteins decreased in abundance.
As with individual proteins, pathways and processes downregulated by HIV infection of primary T
cells are dominated by the effects of accessory proteins (Figure 4A–B). These include the DNA dam-
age response and cell cycle (Vpr) (Greenwood et al., 2019; He et al., 1995; Jowett et al., 1995;
Laguette et al., 2014; Poon et al., 1997; Re et al., 1995; Rogel et al., 1995; Roshal et al., 2003),
cytidine deamination and PP2A activity (Vif) (Greenwood et al., 2016; Harris et al., 2003;
Sheehy et al., 2002) and amino acid transport (Vpu/Nef) (Matheson et al., 2015). Proteins upregu-
lated by HIV are more diverse, with fewer dominant functional clusters. Nonetheless, we saw marked
increases in proteins associated with lipid and sterol metabolism (Figure 4B–C). A similar effect has
been reported in T cell lines at the transcriptional level, and attributed to the expression of Nef
(Shrivastava et al., 2016; van ’t Wout et al., 2005). Similarly, several proteins in these pathways are
indirectly regulated by Vpr (Figure 4C) (Greenwood et al., 2019).
Identification and characterisation of primary T cell-specific HIV targets
Despite the overall agreement with cell line data, 1252/8789 (14%) cellular proteins quantitated here
were not identified in a previous, similar experiment using CEM-T4s (Greenwood et al., 2016). Fur-
thermore, having excluded known accessory-protein dependent changes, 192/650 (30%) proteins
regulated by HIV in primary T cells were either not detected, or not significantly/concordantly regu-
lated, in CEM-T4s (Figure 3C, right panel and Figure 3—figure supplement 3B). These proteins
Figure 3 continued
data in Figure 3—figure supplement 1A. (C) Protein abundances in WT HIV-infected vs mock-infected cells from (A). Volcano plots show statistical
significance (y axis) vs fold change (x axis) for 8789 cellular and six viral proteins quantitated in cells from all three donors (no missing values). Proteins
with Benjamini-Hochberg FDR-adjusted p values (q values) < 0.05 or > 0.05 are indicated (FDR threshold of 5%). Proteins highlighted in each plot are
summarised in the key. Vpr/Vif/Nef/Vpu substrates (green circles) comprise proteins from Figure 2C–D and Figure 2—figure supplement 1B,
excluding negative controls (SAMHD1, APOBEC3B, SERINC1, HLA-C) and HLA-A/B alleles (different in each donor) but including SMUG1 (not identified
in time course proteomic experiment) (Schro¨felbauer et al., 2005) and both quantitated isoforms of PP2R5C (Q13362 and Q13362-4) and ZGPAT
(Q8N5A5 and Q8N5A5-2). Additional Vpr substrates (gold circles) and Vpr-dependent changes (gold crosses) comprise recently described direct and
indirect Vpr targets (Greenwood et al., 2019). HIV-dependent changes only identified in primary T cells (red circles and crosses) comprise proteins
with q < 0.05 either not identified or not concordantly regulated by HIV in CEM-T4s (Greenwood et al., 2016) (and exclude known accessory protein-
dependent changes). Further details on comparator datasets used in this figure are provided in the Materials and methods. (D–E) Abundances of
ARID5A and PTPN22 in mock-infected (grey), WT HIV-infected (red) and DVif HIV-infected (green) primary T cells from (A). Mean abundances (fraction of
maximum) with 95% CIs are shown (D). As well as proteomic analysis, cells from donor A were lysed in 2% SDS and analysed by immunoblot with anti-
ARID5A, anti-PTPN22, anti-Nef and anti-a-tubulin antibodies (E). Same lysates as Figure 5D.
DOI: https://doi.org/10.7554/eLife.41431.010
The following source data and figure supplements are available for figure 3:
Source data 1. Proteins regulated by HIV and/or control lentivectors.
DOI: https://doi.org/10.7554/eLife.41431.011
Figure supplement 1. Additional controls for single time point proteomic experiment.
DOI: https://doi.org/10.7554/eLife.41431.012
Figure supplement 2. Comparison with HIV-dependent changes in CEM-T4s.
DOI: https://doi.org/10.7554/eLife.41431.013
Figure supplement 3. Comparison with HIV-dependent changes in other datasets.
DOI: https://doi.org/10.7554/eLife.41431.014
Figure supplement 4. Proteins regulated by transduction with control lentivectors.
DOI: https://doi.org/10.7554/eLife.41431.015
Figure supplement 5. Comparison with HIV-dependent changes in Kuo et al. (2018).
DOI: https://doi.org/10.7554/eLife.41431.016
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Figure 4. Pathways regulated by HIV in primary T cells. (A–B) Gene Ontology (GO) functional annotation terms enriched amongst upregulated or
downregulated proteins with q < 0.05 in WT HIV-infected vs mock-infected cells from single time point proteomic experiment (Figure 3A). In the
Enrichment Map (Merico et al., 2010) network-based visualisation (A), each node represents a GO term, with node size indicating number of
annotated proteins, edge thickness representing degree of overlap (red, enriched amongst upregulated proteins; blue, enriched amongst
Figure 4 continued on next page
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may represent accessory protein substrates expressed in primary T cells but not T cell lines, or pro-
teins regulated by alternative, cell type-specific mechanisms, such as the interferon response (Fig-
ure 3—figure supplement 3A, right panel) (Vermeire et al., 2016).
We have previously shown that expression of the SBP-DLNGFR selectable marker as a transgene
does not impact the viability, activation or proliferation of primary T cells (Matheson et al., 2014).
Nonetheless, some of the novel changes attributed to HIV in this study could theoretically be sec-
ondary to exposure to VSVg-pseudotyped viral particles, expression of SBP-DLNGFR and/or the
AFMACS workflow, or reflect pre-existing proteomic differences in infected (permissive) cells, com-
pared with the mock-infected bulk population. To exclude these possibilities, we repeated the single
time point proteomic experiment using primary T cells from three new donors and substituting WT
and Vif-deficient HIV-AFMACS for two different control lentivectors expressing SBP-DLNGFR either
as a single transgene (from the SFFV promoter; pSBP-DLNGFR) or in conjunction with HIV-1 Tat
(from the HIV-1 LTR; pTat/SBP-DLNGFR) (Figure 3—figure supplement 4A–C).
As expected, changes in transduced cells were far less extensive than changes induced by HIV
(Figure 3—figure supplement 4D, top and middle panels; compare with Figure 3C). In fact,
amongst 8518 cellular proteins quantitated across nine different conditions, only 37/8518 (0.4%)
were significantly perturbed by one or both lentivectors (q < 0.05), and are summarised in an inter-
active filter table (Figure 3—source data 1). Interestingly, despite evidence of robust transactivation
of the HIV LTR (resulting in high level expression of SBP-DLNGFR at the surface of cells transduced
with pTat/SBP-DLNGFR), no Tat-dependent changes in cellular protein levels were identified (Fig-
ure 3—figure supplement 4C, lower panels and Figure 3—figure supplement 4D, bottom panel).
Most importantly, amongst the 650 proteins significantly regulated by HIV, 576 were quantitated in
the SBP-DLNGFR control experiment, of which only one protein (MYB) was also significantly regu-
lated by the control lentivectors (Figure 3—figure supplement 4D, top and middle panels and Fig-
ure 3—source data 1).
To further validate our proteomic data, we focused on two novel HIV targets with commercially
available antibodies: ARID5A and PTPN22. These proteins were readily identified in proteomic data-
sets from primary T cells (9–14 unique peptides) but not CEM-T4s, and consistently depleted across
all donors with a fold change > 2 (Figure 3D). As expected, depletion was also seen by immunoblot
(Figure 3E).
We previously showed that substrates of different HIV accessory proteins could be distinguished
by their characteristic patterns of temporal regulation in HIV-infected CEM-T4s (Greenwood et al.,
2016), and similar clustering was observed in primary T cells (Figure 2—figure supplement 3A). Vpr
is packaged stoichiometrically in virions (Cohen et al., 1990; Yu et al., 1990; Yuan et al., 1990)
and, since the number of fusogenic HIV particles exceeds the infectious MOI by at least several fold
(Thomas et al., 2007), all cells in our time course experiment were necessarily exposed to incoming
Vpr. Accordingly, depletion of known Vpr substrates was near-maximal by 24 hr in infected (red,
SBP-DLNGFR positive) cells, with partial depletion also seen in uninfected (blue, SBP-DLNGFR nega-
tive) cells (Figure 2E, upper panel). In contrast, since de novo viral protein synthesis is absolutely
required, depletion of known Vif, Nef and Vpu substrates increased progressively from 24 to 48 hr,
and was only seen in HIV-infected (red, SBP-DLNGFR positive) cells (Figure 2E, lower panel).
Based on their patterns of temporal regulation, ARID5A and PTPN22 are therefore very likely to
represent novel Vpr substrates, specific for primary T cells (Figure 2—figure supplement 3B). Con-
sistent with this, another member of the ARID5 subfamily of AT-rich interaction domain (ARID)-
Figure 4 continued
downregulated proteins) and similar GO terms placed close together. Degree of enrichment is mapped to node colour (left side, enriched amongst
upregulated proteins; right side, enriched amongst downregulated proteins) as a gradient from white (no enrichment) to red (high enrichment).
Highlighted nodes (arrow heads) represent GO terms enriched amongst both upregulated and downregulated proteins. In the bar charts (B), the 10
most enriched GO terms (ranked by p value) amongst upregulated (red) and downregulated (blue) proteins are shown, with an indicative Benjamini-
Hochberg FDR threshold of 5% (dashed line). (C) Protein abundances in WT HIV-infected vs mock-infected cells from single time point proteomic
experiment (Figure 3A), with details for volcano plot as in Figure 3C. 57 proteins annotated with the GO term ‘sterol biosynthetic process’
(GO:0016126) are highlighted in red. Amongst these, 15 proteins are regulated by Vpr in CEM-T4s (circles) (Greenwood et al., 2019).
DOI: https://doi.org/10.7554/eLife.41431.017
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containing proteins, ARID5B, is a widely conserved target of Vpr variants from primate lentivuses
(Greenwood et al., 2019), and shares a similar temporal profile (Figure 2—figure supplement 3C).
Comprehensive analysis of recognised and novel Vif targets in primary
T cells
As predicted, both APOBEC3 and PPP2R5 family proteins were depleted in primary CD4+ T cells
infected with WT, but not DVif viruses (Figure 5A–B). Vif-dependent depletion of PPP2R5A-E causes
a marked increase in protein phosphorylation in HIV-infected CEM-T4 T cells, particularly substrates
of the aurora kinases (AURKA/B) (Greenwood et al., 2016). AURKB activity is enhanced by ‘activa-
tion loop’ auto-phosphorylation at threonine 232 (T232), antagonised by PP2A-B56
(Meppelink et al., 2015; Yasui et al., 2004). Accordingly, a marked increase in AURKB T232 phos-
phorylation is seen in CEM-T4s transduced with Vif as a single transgene (Figure 5C). We therefore
confirmed depletion of PPP2R5D by immunoblot of AFMACS-selected primary T cells and, as a func-
tional correlate, observed increased AURKB phosphorylation (Figure 5D).
Besides these known substrates, we also noted differential regulation of several other proteins in
primary T cells infected with WT vs DVif viruses (Figure 5A). Modest changes in PPP2R1A, PPP2R1B
and PPP2CA (catalytic/structural subunits of the trimeric PP2A holoenzyme) and PPFIA1 and SGO1
(known PP2A interactors) (Liu et al., 2014; Tang et al., 2006; Xu et al., 2009) are likely to be sec-
ondary to destabilisation of PP2A by PPP2R5 depletion, or reflect proximity of the holoenzyme to
the Vif-cullin E3 ligase complex (Figure 5B). Conversely, DPH7 and FMR1 are not known to interact
physically with PP2A, and show more profound and consistent depletion (Figure 5E). We therefore
suspected these proteins to be novel Vif substrates.
To confirm these findings, we first re-examined our proteomic data from CEM-T4s
(Greenwood et al., 2016). Unlike ARID5A and PTPN22, DPH7 and FMR1 are expressed in CEM-T4
as well as primary T cells, and only decreased in abundance in HIV-infected cells in the presence of
Vif (Figure 5E). Next, we confirmed Vif-dependent depletion of both proteins by immunoblot, in
cells infected with WT (but not DVif) viruses (Figure 5F). Finally, we repeated these observations in
cells transduced with Vif as a single transgene (Figure 5G). Vif is therefore both necessary and suffi-
cient for depletion of DPH7 and FMR1 and, taken together with APOBEC3 and PPP2R5 family pro-
teins/interactors, we can account for all significant Vif-dependent changes in the natural target cell
of HIV infection.
Discussion
Compared with FACS, bead-based magnetic sorting is fast, simple and scalable for simultaneous
processing of multiple samples and large cell numbers (Plouffe et al., 2015). In conventional, anti-
body-based immunomagnetic selection, cells remain coated with beads and antibody-antigen com-
plexes, risking alteration of their behaviour or viability through cross-linking of cell-surface receptors
or internalisation of ferrous beads (Bernard et al., 2002; Plouffe et al., 2015; Stanciu et al., 1996).
Conversely, AFMACS-based selection is antibody free, and selected cells are released from the
beads by incubation with biotin, suitable for a full range of downstream applications
(Matheson et al., 2014). The HIV-AFMACS virus described in this study allows routine isolation of
HIV-infected cells subjected to an MOI  1, avoiding artefacts associated with high MOIs and facili-
tating experiments in primary cells, where high levels of infection are difficult to achieve in practice.
To demonstrate the utility of this system and provide a resource for the community, we have gen-
erated the first high coverage proteomic atlas of HIV-infected primary human CD4+ T cells. As well
as identifying HIV-dependent changes in cells from multiple donors, viral regulation may be assessed
against a background of endogenous regulation triggered by T cell activation. Unlike T cell lines, pri-
mary T cells express a full range of proteins relevant to HIV infection in vivo, and are not confounded
by the genetic and epigenetic effects of transformation. Furthermore, proteins unique to primary T
cells were significantly more likely to be regulated by HIV infection than proteins detected in both
primary T cells and CEM-T4s (131/1252 = 10.5% vs 519/7537 = 6.9%; p < 0.0001, two-tailed Fisher’s
exact test). Our data validate many, but not all, previously reported HIV accessory protein targets.
For some Vpu/Nef substrates, such as NTB-A and CCR7, downregulation from the plasma mem-
brane may occur in the absence of protein degradation (Bolduan et al., 2013; Ramirez et al., 2014;
Shah et al., 2010). For others, such as ICAM-1/3, accessory protein expression may prevent
Naamati et al. eLife 2019;8:e41431. DOI: https://doi.org/10.7554/eLife.41431 11 of 27
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Figure 5. Vif-dependent cellular targets in primary T cells. (A) Protein abundances in WT HIV-infected vs DVif HIV-infected cells from single time point
proteomic experiment (Figure 3A). Statistical significance (y axis) vs fold change (x axis) is shown for 8795 cellular and viral proteins quantitated in cells
from all three donors (no missing values). Proteins with Benjamini-Hochberg FDR-adjusted p values (q values) < 0.05 or > 0.05 are indicated (FDR
threshold of 5%). Highlighted groups of differentially regulated proteins are summarised in the key, including two quantitated isoforms of PP2R5C
Figure 5 continued on next page
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upregulation, without reducing levels below baseline (Sugden et al., 2017). Alternatively, and partic-
ularly where targets have been discovered using model cell line or overexpression systems, regula-
tion may not be quantitatively significant at the protein level in the context and/or natural cell of HIV
infection.
Previous temporal proteomic analyses of HIV-infected primary human CD4+ T cells were ham-
pered by extremely limited coverage of the cellular proteome (< 2000 proteins), and did not detect
regulation of known or novel HIV accessory protein targets (Chan et al., 2009; Nemeth et al.,
2017). A more recent study quantitated 7761 proteins in FACS-sorted T cells at a single time point
96 hr post-infection with an R5-tropic, GFP-expressing Nef-deficient virus (Kuo et al., 2018). Deple-
tion of several accessory protein targets (including APOBEC3 and PPP2R5 families) was confirmed,
and many proteins differentially regulated at 96 hr were also regulated at 48 hr in our study (Fig-
ure 3—figure supplement 5A). In keeping with the late time point, changes were dominated by
pathways involved in cell death and survival, and factors maintaining viability of HIV-infected T cells
(such as BIRC5) were enriched. Conversely, the full dataset is not available, effect sizes were gener-
ally compressed (Figure 3—figure supplement 5A), and 413/650 (64%) of the HIV-dependent
changes identified in our study were obscured, including depletion of ARID5A, PTPN22, DPH7 and
19/51 known accessory protein substrates (Figure 3—figure supplement 5B).
Compared with other studies, the depth of proteomic coverage reported here not only increases
the number of proteins identified, but also reduces the variability in quantitation (‘noise’). For exam-
ple, > 90% of proteins are quantitated using two or more unique peptides. Furthermore, the homo-
geneous populations of cells analysed (> 90% infected) maximise effect sizes (‘signal’), and ensure
that proteins exhibiting the most statistically significant differences are also those with the biggest
fold changes. Because the ‘signal-to-noise ratio’ is high, positive controls (known viral targets)
behave extremely consistently across our datasets (as shown, for example, in Figure 3C and Fig-
ure 2—figure supplement 1B), and it is possible to make predictions about other cellular proteins
falling in the same regions of the volcano plots, and/or exhibiting similar temporal profiles. Our
results are therefore useful as a resource (that is, general description of all protein changes), not just
as a screen (to identify far outliers).
To enhance viral titers, avoid Env-dependent cytotoxicity, enable synchronous single round infec-
tions and bypass co-receptor-dependent targeting of T cell lineages with pre-existing proteomic dif-
ferences, we used an Env-deficient proviral backbone and pseudotyped viruses with VSVg.
Pseudotyping with VSVg redirects HIV viral entry away from the plasma membrane towards an endo-
cytic pathway (Aiken, 1997), and may abrogate Env-dependent integrin (Arthos et al., 2008) and
chemokine co-receptor (Wu and Yoder, 2009) signalling early in infection. To limit the impact of
these effects, we focussed our analysis on cellular proteins progressively regulated over 48 hr infec-
tion. Since only 1/650 HIV-dependent perturbations at this time point was also observed in cells
transduced with control lentiviral particles, it is very unlikely that pseudotyping with VSVg per se
caused significant artefactual proteomic changes in our datasets (false positives). Nonetheless, it is
Figure 5 continued
(Q13362 and Q13362-4) and FMR1 (Q06787 and Q06787-2). (B) Abundances of Vif-dependent PPP2R5 family and related proteins highlighted in a) in
mock-infected (grey), WT HIV-infected (red) and DVif HIV-infected (green) cells from single time point proteomic experiment (Figure 3A). Mean
abundances (fraction of maximum) with 95% CIs are shown. Only the canonical isoform of PPP2R5C (Q13362) is shown. (C) Activation of AURKB by Vif.
CEM-T4s were mock-transduced or transduced with control (pCtrl) or Vif-expressing (pVif) lentiviruses for 48 hr (62–78% GFP+), lysed in 2% SDS and
analysed by immunoblot with anti-phospho-AURK (T232), anti-total AURKB, anti-Vif and anti-a-tubulin antibodies. (D) Vif-dependent activation of
AURKB. AFMACS-selected (LNGFR+) HIV-infected cells from Figure 3A (donor A) were lysed in 2% SDS and analysed by immunoblot with anti-
PPP2R5D, anti-phospho-AURK (T232), anti-total AURKB and anti-Vif antibodies. Same lysates as Figure 3E. (E) Abundances of DPH7 and FMR1 in mock-
infected (grey), WT HIV-infected (red) and DVif HIV-infected (green) primary T cells from single time point proteomic experiment (Figure 3A) and CEM-
T4s (Greenwood et al., 2016). Mean abundances (fraction of maximum) with 95% CIs intervals are shown. Only the canonical isoform of FMR1
(Q06787) is shown. (F) Vif-dependent depletion of DPH7 and FMR1. CEM-T4s were mock-infected or infected with WT or DVif HIV-AFMACS viruses for
48 hr (77–82% LNGFR +cells), lysed in 2% SDS, and analysed by immunoblot with anti-DPH7, ant-FMR1, anti-Vif and anti-a-tubulin antibodies. (G)
Depletion of DPH7, FMR1 and PPP2R5D by Vif. CEM-T4s were mock-transduced or transduced with control (pCtrl) or Vif-expressing (pVif) lentiviruses
for 48 hr (86–88% GFP +cells), lysed in 2% SDS and analysed by immunoblot with anti-phospho-AURK, anti-total AURKB, anti-Vif and anti- a-tubulin
(loading control) antibodies.
DOI: https://doi.org/10.7554/eLife.41431.018
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possible that the absence of Env-CD4/co-receptor interactions resulted in an underestimate of
proteomic changes induced by full length HIV (false negatives), which may vary depending on tro-
pism of the virus (Wiredja et al., 2018; Wojcechowskyj et al., 2013).
Temporal profiling is particularly well suited to identifying and characterising host factors regu-
lated directly by viral proteins. Because of the need for de novo synthesis of cell surface SBP-D
LNGFR, it is not possible to perform AFMACS-based selection of HIV-infected primary T cells very
early in infection. Nonetheless, even with a first time point 24 hr post-infection, we were able to suc-
cessfully categorise cellular accessory protein targets according to their patterns of regulation in the
time course proteomic experiment. In fact, as we show here, accessory proteins account for much or
most of the proteomic remodelling in HIV-infected cells. The abundance of direct accessory protein
targets likely explains why proteins and processes/pathways downregulated by HIV in primary T cells
correlate so well with changes seen in T cell lines, and are robust to inter-individual variation. In com-
parison, upregulated proteins concord less well with changes in T cell lines, and functional effects
are less homogeneous. This may be because upregulated proteins reflect indirect effects (for exam-
ple, secondary changes in transcription), which are more likely to be cell-type specific.
Amongst the HIV accessory proteins, Vif was thought until recently to exclusively degrade APO-
BEC3 family cytidine deaminases. As well as confirming equivalently-potent Vif-dependent depletion
of PPP2R5 family phosphatase subunits in primary T cells, our data revealed unexpected Vif-depen-
dent depletion of DPH7 and FMR1. Further work will be required to confirm that these proteins are
recruited directly for degradation by the ubiquitin-proteasome system, determine whether (like
APOBEC3 and PPP2R5 proteins) they are antagonised by Vif variants from diverse primate and non-
primate lentiviral lineages, and identify relevant in vitro virological phenotypes associated with target
depletion. Nonetheless, FMR1 is already known to reduce HIV virus infectivity when over-expressed
in producer cells (Pan et al., 2009), and the other novel targets highlighted in this study also impact
processes relevant for HIV replication, such as inflammatory cytokine signalling (ARID5A)
(Higa et al., 2018), T cell activation (PTPN22) (Hasegawa et al., 2004) and translational fidelity
(DPH7) (Carette et al., 2009; Ortiz et al., 2006). The diversity of these targets underscores the ben-
efit of an unbiased, systems-level approach to viral infection, and the capacity of the resources pre-
sented in this study to reveal unsuspected aspects of the host-virus interaction in the natural target
cell of HIV infection.
Materials and methods
Key resources table
Reagent type
(species)
or resource Designation
Source or
reference Identifiers
Additional
information
Cell line CEM-T4 NIH AIDS
Reagent
Program
Cat. #: 117
Antibody Mouse monoclonal
BV421-conjugated
anti-CD4
BioLegend Cat. #: 317434 Flow cytometry
Antibody Mouse monoclonal
PE-conjugated
anti-CD4
BD Biosciences Cat. #: 561843 Flow cytometry
Antibody Mouse monoclonal
PE-conjugated
anti-tetherin
BioLegend Cat. #: 348405 Flow cytometry
Antibody Mouse monoclonal
AF647-conjugated
anti-LNGFR
BioLegend Cat. #: 345114 Flow cytometry
Antibody Mouse monoclonal
FITC-conjugated
anti-LNGFR
BioLegend Cat. #: 345103 Flow cytometry
Continued on next page
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Continued
Reagent type
(species)
or resource Designation
Source or
reference Identifiers
Additional
information
Antibody Rabbit monoclonal
anti-PPP2R5D
Abcam Cat. #:
ab188323
Immunoblot
Antibody Mouse monoclonal anti-HIV-
1 Vif
NIH AIDS
Reagent Program
Cat. #: 6459 Immunoblot
Antibody Mouse monoclonal anti-p24 Abcam Cat. #: ab9071 Immunoblot
Antibody Mouse monoclonal
anti-HIV-1 Nef
NIH AIDS
Reagent Program
Cat. #: 3689 Immunoblot
Antibody Rabbit monoclonal
anti-PTPN22
(D6D1H)
Cell Signalling
Technology
Cat. #: 14693 Immunoblot
Antibody Mouse monoclonal
anti-ARID5A
GeneTex Cat. #:
GTX631940
Immunoblot
Antibody Rabbit polyclonal
anti-FMR1 (FMRP)
Cell Signalling Technology Cat. #: 4317 Immunoblot
Antibody Rabbit polyclonal
anti-DPH7
Atlas Antibodies Cat. #: HPA022911 Immunoblot
Antibody Mouse monoclonal
anti-a-tubulin
Cell Signalling
Technology
Cat. #: 3873 Immunoblot
Antibody Mouse monoclonal anti-b-actin Sigma Cat. #: A5316 Immunoblot
Antibody Rabbit polyclonal
anti-total AURKB
Cell Signalling
Technology
Cat. #: 3094 Immunoblot
Antibody Rabbit monoclonal
anti-phospho-AURK
Cell Signalling Technology Cat. #: 2914 Immunoblot
Recombinant
DNA reagent
HIV-AFMACS This paper GenBank: MK435310 pNL4-3-DEnv-
Nef-P2A-SBP-
DLNGFR proviral
construct (see
Materials and
methods)
Recombinant
DNA reagent
pCtrl (Matheson et al., 2014) Not applicable pHRSIN-SE-P2A-
SBP-DLNGFR-W
expression vector
Recombinant
DNA reagent
pVif This paper Not applicable pHRSIN-SE-P2A-
Vif-hu-W expression
vector (see Materials
and methods)
Recombinant
DNA reagent
pSBP-DLNGFR This paper Not applicable pHRSIN-S-P2A-
SBP-DLNGFR-W
expression vector
(see Materials and
methods)
Recombinant
DNA reagent
pTat/SBP-DLNGFR This paper Not applicable pLTR-Tat-P2A-
SBP-DLNGFR
expression vector
(see Materials
and methods)
Commercial
assay or kit
Dynabeads Untouched Human CD4
T Cells kit
Invitrogen Cat. #: 11346D
Commercial
assay or kit
Dynabeads Human T-
Activator CD3/CD28
Gibco Cat. #: 11132D
Commercial
assay or kit
Dynabeads Biotin Binder Invitrogen Cat. #: 11047
Commercial
assay or kit
iST-NHS Sample Preparation Kit PreOmics Cat. #: P.O.00030
Continued on next page
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Continued
Reagent type
(species)
or resource Designation
Source or
reference Identifiers
Additional
information
Commercial
assay or kit
S-Trap micro MS Sample Preparation Kit Protifi Cat. #: C02-micro
Commercial
assay or kit
TMT10plex Isobaric Label Reagent Set Thermo Scientific Cat. #: 90110
Chemical
compound,
drug
Lympholyte-H Cedarlane Laboratories Cat. #: CL5020
Chemical
compound,
drug
IL-2 PeproTech Cat. #: 200–02 Recombinant
human IL-2
Chemical
compound,
drug
Lenti-X Concentrator Clontech Cat. #: 631232
Software,
algorithm
Proteome Discoverer 2.1 Thermo Scientific RRID: SCR_014477
Software,
algorithm
DAVID 6.8 (Huang et
al., 2009a;
Huang et al.,
2009b)
RRID: SCR_001881 https://david.
ncifcrf.gov/
Software,
algorithm
Cytoscape 3.6.1 (Shannon et
al., 2003)
RRID: SCR_003032 http://cytoscape.org/
Software,
algorithm
Enrichment Map 3.1.0
Cystoscape plugin
(Merico et
al., 2010)
RRID:
SCR_016052
http://baderlab.
org/Software/
EnrichmentMap
Software,
algorithm
Cluster 3.0 (de Hoon et
al., 2004)
RRID:
SCR_013505
http://bonsai.
hgc.jp/~mdehoon/
software/cluster/
software.htm
Software,
algorithm
Java TreeView 1.1.6r4 (Saldanha, 2004) RRID:SCR_013503 http://jtreeview.
sourceforge.net
General cell culture
CEM-T4 T cells (CEM-T4s) (Foley et al., 1965) were obtained directly (< 1 year) from the AIDS
Reagent Program, Division of AIDS, NIAD, NIH: Dr J.P. Jacobs and cultured in RPMI supplemented
with 10% FCS, 100units/ml penicillin and 0.1 mg/ml streptomycin at 37˚C in 5% CO2. HEK-293T cells
were obtained from Lehner laboratory stocks (authenticated by STR profiling [Menzies et al., 2018;
Miles et al., 2017]) and cultured in DMEM supplemented with 10% FCS, 100units/ml penicillin and
0.1 mg/ml streptomycin at 37˚C in 5% CO2. All cells were confirmed to be mycoplasma negative
(Lonza MycoAlert).
Primary cell isolation and culture
Primary human CD4+ T cells were isolated from peripheral blood by density gradient centrifugation
over Lympholyte-H (Cedarlane Laboratories) and negative selection using the Dynabeads Untouched
Human CD4 T Cells kit (Invitrogen) according to the manufacturer’s instructions. Purity was assessed
by flow cytometry for CD3 and CD4 and routinely found to be  95%. Cells were activated using
Dynabeads Human T-Activator CD3/CD28 beads (Gibco) according to the manufacturer’s instruc-
tions and cultured in RPMI supplemented with 10% FCS, 30 U/ml recombinant human IL-2 (Pepro-
Tech), 100units/ml penicillin and 0.1 mg/ml streptomycin at 37˚C in 5% CO2.
Ethics statement
Ethical permission for this study was granted by the University of Cambridge Human Biology
Research Ethics Committee (HBREC.2017.20). Written informed consent was obtained from all vol-
unteers prior to providing blood samples.
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HIV-1 molecular clones
pNL4-3-DEnv-EGFP (Zhang et al., 2004) was obtained from the AIDS Reagent Program, Division of
AIDS, NIAD, NIH: Drs Haili Zhang, Yan Zhou, and Robert Siliciano and the complete proviral
sequence verified by Sanger sequencing (Source BioScience). Derived from the HIV-1 molecular
clone pNL4-3, it encodes EGFP in the env ORF), resulting in a large, critical env deletion and expres-
sion of a truncated Env-EGFP fusion protein retained in the endoplasmic reticulum (ER) by a 3’ KDEL
ER-retention signal.
The SBP-DLNGFR selection marker comprises the high-affinity 38 amino acid SBP fused to the
N-terminus of a truncated (non-functional) member of the Tumour Necrosis Factor Receptor super-
family (LNGFR) (Matheson et al., 2014). As a type I transmembrane glycoprotein, expression at the
cell surface requires a 5’ signal peptide.
To replace EGFP with SBP-DLNGFR (generating pNL4-3-DEnv-SBP-DLNGFR) a synthetic gene
fragment (gBlock; Integrated DNA Technologies, IDT) was incorporated into pNL4-3-DEnv-EGFP by
Gibson assembly between SalI/BsaBI sites (gBlock #1; Supplementary file 1). In this construct, SBP-
DLNGFR is fused with the endogenous Env signal peptide.
To express SBP-DLNGFR downstream of nef and a ‘self-cleaving’ Porcine teschovirus-1 2A (P2A)
peptide (generating pNL4-3-DEnv-EGFP-Nef-P2A-SBP-DLNGFR) a gBlock (IDT) was incorporated
into pNL4-3-DEnv-EGFP by Gibson assembly between HpaI/XhoI sites (gBlock #2;
Supplementary file 1). In this construct, SBP-DLNGFR is co-translated with codon-optimised Nef
(Nef-hu) and includes an exogenous murine immunoglobulin (Ig) signal peptide. SBP-DLNGFR was
located downstream (rather than upstream) of Nef-hu to avoid disruption of Nef myristoylation by
addition of a 5’ proline residue following P2A ‘cleavage’.
To express SBP-DLNGFR downstream of nef and an Encephalomyocarditis virus (EMCV) internal
ribosome entry site (IRES; generating pNL4-3-DEnv-EGFP-Nef-IRES-SBP-DLNGFR) a gBlock (IDT) was
incorporated into pNL4-3-DEnv-EGFP by Gibson assembly between HpaI/XhoI sites (gBlock #3;
Supplementary file 1). In this construct, SBP-DLNGFR is translated independently of Nef-hu and
includes an exogenous murine Ig signal peptide. A widely-used replication-competent HIV EGFP
reporter virus was previously generated using a similar approach (Schindler et al., 2006;
Schindler et al., 2003).
In all constructs, Nef or Nef-hu expression is mediated by the WT HIV LTR promoter and naturally
occurring splice sites. In constructs with a P2A peptide or IRES, the use of codon-optimised Nef-hu
minimises homology with the U3 region of the 3’ LTR (overlapped by the endogenous nef sequence)
and reduces the risk of recombination.
To remove EGFP from constructs with a P2A peptide or IRES, a gBlock (IDT) was incorporated by
Gibson assembly between SalI/BsaBI sites (gBlock #4; Supplementary file 1). To avoid generating a
truncated protein product fused to the Env signal peptide, the env start codon and other potential
out of frame start codons in the vpu ORF were disrupted with point mutations, whilst maintaining
the Vpu protein sequence. Redundant env sequence was minimised, without disrupting the Rev
response element (RRE).
To truncate the U3 region of the 3’ LTR in constructs with a P2A peptide or IRES (with or without
EGFP), a gBlock (IDT) was incorporated by Gibson assembly between XhoI/NaeI sites (gBlock #5;
Supplementary file 1). Previous studies have shown that, in the presence of an intact nef ORF, the
overlap between nef and the U3 region is dispensable for HIV gene expression and replication
(Mu¨nch et al., 2005).
To generate a Vif-deficient HIV-AFMACS molecular clone (pNL4-3-DVif-DEnv-Nef-P2A-SBP-D
LNGFR), a restriction fragment encoding a stop codon early in the Vif ORF (after the final in-frame
start codon) was subcloned from pNL4-3-DVif-DEnv-EGFP (Greenwood et al., 2016) into pNL4-3-D
Env-Nef-P2A-SBP-DLNGFR (HIV-AFMACS) between AgeI/PflMI sites.
Where appropriate, additional unique restriction sites were included to facilitate future cloning.
All sequences were verified by Sanger sequencing (Source BioScience). The complete HIV-AFMACS
sequence is available in Supplementary file 1.
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Lentivectors for transgene expression
pHRSIN-SE-P2A-SBP-DLNGFR-W (referred to as pCtrl in this paper, in which EGFP and SBP-DLNGFR
expression are mediated by the spleen focus-forming virus (SFFV) promoter and coupled by a P2A
peptide) has been previously described (Matheson et al., 2014).
For over-expression of SBP-DLNGFR as a single transgene, overlapping DNA oligomers (Sigma)
encoding a short peptide linker were incorporated into pCtrl in place of EGFP by restriction cloning
between BamHI/NotI sites to generate pHRSIN-S-P2A-SBP-DLNGFR-W (referred to as pSBP-D
LNGFR in this paper).
For over-expression of HIV-1 Tat and SBP-DLNGFR from the HIV-1 LTR promoter, P2A-SBP-D
LNGFR was PCR-amplified from HIV-AFMACS and incorporated into pLTR-Tat-IRES-GFP (pEV731, a
kind gift from Eric Verdin [Jordan et al., 2001]) by Gibson assembly with a bridging gBlock (IDT)
between ClaI/XhoI sites. In this construct (pLTR-Tat-P2A-SBP-DLNGFR, referred to as pTat/SBP-D
LNGFR in this paper), Tat and SBP-DLNGFR expression are coupled by a P2A peptide, replacing
Tat-IRES-GFP in the original lentivector.
For over-expression of codon optimised NL4-3 Vif (Vif-hu), a gBlock (IDT) was incorporated into
pCtrl in place of SBP-DLNGFR by Gibson assembly between KpnI/XhoI sites to generate pHRSIN-SE-
P2A-Vif-hu-W (referred to as pVif in this paper, in which EGFP and Vif-hu expression are coupled by
a P2A peptide).
Viral stocks
VSVg-pseudotyped NL4-3-DEnv-based viral stocks were generated by co-transfection of HEK-293 T
cells with pNL4-3-DEnv molecular clones and pMD.G at a ratio of 9:1 (mg) DNA and a DNA:FuGENE
6 ratio of 1 mg:6 ml. Media was changed the next day and viral supernatants harvested and filtered
(0.45 mm) at 48 hr prior to concentration with Lenti-X Concentrator (Clontech) and storage at  80˚C.
VSVg-pseudotyped lentivector stocks were generated by co-transfection of 293Ts with lentivec-
tor, p8.91 and pMD.G at a ratio of 2:1:1 (mg) DNA and a DNA:FuGENE 6 ratio of 1 ug:3 ml. Viral
supernatants were harvested, filtered, concentrated and stored as per NL4-3-DEnv-based viral
stocks.
All viruses and lentivectors were titered by infection/transduction of known numbers of relevant
target cells with known volumes of viral stocks under standard experimental conditions, followed by
flow cytometry for SBP-DLNGFR or EGFP plus/minus CD4 at 48 hr to identify the fraction of infected
cells (f) containing at least one transcriptionally active provirus (SBP-DLNGFR or EGFP positive plus/
minus CD4 low). The number of infectious/transducing units present was then calculated by assum-
ing a Poisson distribution (where f = 1-e-MOI). Typically, a dilution series of each viral stock was
tested, and titer determined by linear regression of -ln(1-f) on volume of virus.
T cell infections
CEM-T4s were infected/transduced by spinoculation at 800 g for 2 hr in a non-refrigerated benchtop
centrifuge in complete media supplemented with 10 mM HEPES. Primary human CD4+ T cells were
infected/transduced using the same protocol 48 hr after activation with CD3/CD28 Dynabeads.
Unlike CEM-T4s, permissivity of infected primary T cells varies between donors/experiments, and
the maximum fraction of infected cells in viral dilution series is often around 50% for single round
infections, even at high MOI. In practice, we therefore aimed to use sufficient infectious/transducing
units to achieve approximately 30% infection, corresponding to a ‘nominal’ MOI  0.5 (assuming a
Poisson distribution). This ensured that, even if only 50% of cells were permissive, the ‘effective’
MOI would still be  1.
Antibody-Free magnetic cell sorting (AFMACS)
AFMACS-based selection of CEM-T4 or primary human CD4+ T cells using the streptavidin-binding
SBP-DLNGFR affinity tag was carried out essentially as previously described (Matheson et al., 2014).
For primary T cells, CD3/CD28 Dynabeads were first removed using a DynaMag-2 magnet (Invitro-
gen). 24 or 48 hr post-infection, washed cells were resuspended in incubation buffer (IB; Hank’s bal-
anced salt solution, 2% dialysed FCS, 1x RPMI Amino Acids Solution (Sigma), 2 mM L-glutamine, 2
mM EDTA and 10 mM HEPES) at 10e7 cells/ml and incubated with Dynabeads Biotin Binder (Invitro-
gen) at a bead-to-total cell ratio of 4:1 for 30 min at 4˚C. Bead-bound cells expressing SBP-DLNGFR
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were selected using a DynaMag-2 (Invitrogen), washed to remove uninfected cells, then released
from the beads by incubation in complete RPMI with 2 mM biotin for 15 min at room temperature
(RT). Enrichment was routinely assessed by flow cytometry pre- and post-selection.
Proteomic analysis
Sample preparation
For TMT-based whole cell proteomic analysis of primary human CD4+ T cells, resting or activated
cells were washed with ice-cold PBS with Ca/Mg pH 7.4 (Sigma) and frozen at  80˚C. Samples were
lysed, reduced, alkylated, digested and labelled with TMT reagents (Thermo Scientific) using either
iST-NHS (PreOmics GmbH; time course and single time point experiments) or S-Trap (Protifi; SBP-D
LNGFR control experiment) sample preparation kits, according to the manufacturers’ instructions.
Typically, 5e6 resting or 1e6 activated cells were used for each condition.
Off-line high pH reversed-phase (HpRP) peptide fractionation
HpRP fractionation was conducted on an Ultimate 3000 UHPLC system (Thermo Scientific) equipped
with a 2.1 mm 15 cm, 1.7 mm Acquity BEH C18 column (Waters, UK). Solvent A was 3% ACN, sol-
vent B was 100% ACN, and solvent C was 200 mM ammonium formate (pH 10). Throughout the
analysis C was kept at a constant 10%. The flow rate was 400 mL/min and UV was monitored at 280
nm. Samples were loaded in 90% A for 10 min before a gradient elution of 0–10% B over 10 min
(curve 3), 10–34% B over 21 min (curve 5), 34–50% B over 5 min (curve 5) followed by a 10 min wash
with 90% B. 15 s (100 mL) fractions were collected throughout the run. Peptide-containing fractions
were orthogonally recombined into 24 fractions (e.g. fractions 1, 25, 49, 73 and 97) and dried in a
vacuum centrifuge. Fractions were stored at  80˚C prior to analysis.
Mass spectrometry
Data were acquired on an Orbitrap Fusion mass spectrometer (Thermo Scientific) coupled to an Ulti-
mate 3000 RSLC nano UHPLC (Thermo Scientific). HpRP fractions were resuspended in 20 ml 5%
DMSO 0.5% TFA and 10 uL injected. Fractions were loaded at 10 ml/min for 5 min on to an Acclaim
PepMap C18 cartridge trap column (300 um 5 mm, 5 um particle size) in 0.1% TFA. Solvent A was
0.1% FA and solvent B was ACN/0.1% FA. After loading, a linear gradient of 3–32% B over 3 hr was
used for sample separation over a column of the same stationary phase (75 mm  50 cm, 2 mm parti-
cle size) before washing at 90% B and re-equilibration.
An SPS/MS3 acquisition was used for all samples and was run as follows. MS1: Quadrupole isola-
tion, 120’000 resolution, 5e5 AGC target, 50 ms maximum injection time, ions injected for all paralle-
lisable time. MS2: Quadrupole isolation at an isolation width of m/z 0.7, CID fragmentation (NCE 35)
with the ion trap scanning out in rapid mode from m/z 120, 8e3 AGC target, 70 ms maximum injec-
tion time, ions accumulated for all parallelisable time. In synchronous precursor selection mode the
top 10 MS2 ions were selected for HCD fragmentation (65NCE) and scanned out in the orbitrap at
50’000 resolution with an AGC target of 2e4 and a maximum accumulation time of 120 ms, ions
were not accumulated for all parallelisable time. The entire MS/MS/MS cycle had a target time of 3
s. Dynamic exclusion was set to ±10 ppm for 90 s, MS2 fragmentation was trigged on precursor ions
5e3 counts and above.
Data processing and analysis
Spectra were searched by Mascot within Proteome Discoverer 2.1 in two rounds. The first search
was against the UniProt Human reference proteome (26/09/17), the HIV-AFMACS proteome and
compendium of common contaminants (GPM). The second search took all unmatched spectra from
the first search and searched against the human trEMBL database (Uniprot, 26/09/17). For time
course and single time point experiments, the following search parameters were used. MS1 Tol: 10
ppm. MS2 Tol: 0.6 Da. Fixed Mods: Ist-alkylation (+113.084064 Da) (C) and TMT (N-term, K). Var
Mods: Oxidation (M). Enzyme: Trypsin (/P). For the SBP-DLNGFR control experiment, Carbamido-
methyl (C) modification was used in place of Ist-Alkylation. MS3 spectra were used for reporter ion-
based quantitation with a most confident centroid tolerance of 20 ppm. Peptide spectrum match
(PSM) false discovery rate (FDR) was calculated using Mascot percolator and was controlled at
0.01% for ‘high’ confidence PSMs and 0.05% for ‘medium’ confidence PSMs. Normalisation was
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automated and based on total s/n in each channel. Proteins/peptides satisfying at least a ‘medium’
FDR confidence were taken forth to statistical analysis in R. This consisted of a moderated T-test
(Limma) with Benjamini-Hochberg correction for multiple hypotheses to provide a q value for each
comparison (Schwa¨mmle et al., 2013). Further data manipulation and general statistical analysis
(including principal component analysis) was conducted using Excel, XLSTAT and GraphPad Prism 7.
All mass spectrometry proteomics data from this study have been deposited to the ProteomeX-
change Consortium via the PRIDE (Vizcaı´no et al., 2016) partner repository with the dataset identi-
fier PXD012263 and 10.6019/PXD012263 (accessible at http://proteomecentral.proteomexchange.
org).
For functional analysis of proteins significantly downregulated or upregulated by WT HIV
(q < 0.05) in the single time point proteomic experiment (Figure 3A), enrichment of Gene Ontology
(GO) Biological Process (GOTERM_BP_FAT) and Molecular Function (GOTERM_MF_FAT) terms
against a background of all proteins quantitated was determined using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) 6.8 (accessed on 22/7/2018 at https://david.ncifcrf.
gov/) with default settings (Huang et al., 2009a; Huang et al., 2009b). Human proteins annotated
to GO:0016126 (sterol biosynthetic process) were retrieved from AmiGO 2 (accessed on 27/7/2018
at http://amigo.geneontology.org/amigo) (Carbon et al., 2009). To account for redundancy
between annotations, enriched GO terms were visualised using the Enrichment Map 3.1.0 plugin
(Merico et al., 2010) for Cytoscape 3.6.1. (downloaded from http://cytoscape.org/) (Shannon et al.,
2003) with default settings (q value cut-off of 0.1) and sparse-intermediate connectivity. Clusters
were manually labelled to highlight the prevalent biological functions amongst each set of related
annotations.
For clustering according to profiles of temporal expression, known accessory protein substrates
from Figure 2C–D and Figure 2—figure supplement 1B and additional Vpr substrates shown in
Figure 3C were analysed using Cluster 3.0 (downloaded from http://bonsai.hgc.jp/~mdehoon/soft-
ware/cluster/software.htm) (de Hoon et al., 2004) and visualised using Java TreeView 1.1.6r4 (down-
loaded from http://jtreeview.sourceforge.net) (Saldanha, 2004). Only proteins significantly
downregulated by WT HIV (q < 0.05) in the single time point proteomic experiment (Figure 3A)
were included. Where more than one isoform was quantitated, only the canonical isoform was used
(PPP2R5C, Q13362; ZGPAT, Q8N5A5; NUSAP1, Q9BXS6). Data from the time course proteomic
experiment (Figure 2A) were expressed as log2(ratio)s of abundances in experimental (Expt):control
(Ctrl) cells for each condition/time point, and range-scaled to highlight patterns of temporal expres-
sion relative to the biological response range (minimum-maximum) for each protein. Agglomerative
hierarchical clustering was performed using uncentered Pearson correlation and centroid linkage
(Eisen et al., 1998).
Comparison with CEM-T4 T cells
To compare results between primary and transformed T cells at a similar depth of proteomic cover-
age, we re-analysed TMT-labelled peptide eluates from a previous study (Greenwood et al., 2016)
conducted in CEM-T4s spinoculated in triplicate with VSVg-pseudotyped NL4-3-DEnv-EGFP WT or
DVif viruses at an MOI of 1.5. This extended analysis consisted of reinjection of HpRP fractions on
longer (3 hr) gradients using a higher performance (75 as opposed to 50 cm) analytical column and
the MS parameters employed in this study. In total, the new CEM-T4 dataset covered 8065 proteins,
comparable with the datasets from primary T cells described here.
Comparisons with other published datasets
A previous study quantitated 7816 proteins at multiple time points following in vitro activation of
naı¨ve (CD45RA+ CCR7+) primary human CD4+ human T cells with plate-bound anti-CD23 and anti-
CD28 antibodies (Geiger et al., 2016). For comparison with this study, a filtered list of 5907 proteins
quantitated in at least two samples from both resting cells and cells activated for 48 hr was used.
We have recently characterised 34 new Vpr substrates, together with further, extensive Vpr-
dependent changes (downregulated and upregulated proteins) in HIV-infected CEM-T4s
(Greenwood et al., 2019). For comparison with this study, a list of 1388 proteins concordantly regu-
lated by Vpr (q < 0.05) in the context of both viral infection and Vpr-bearing virus-like particles was
compiled from the published datasets.
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RUNX1 target genes were previously found to be regulated by Vif at a transcriptional level
because of competition for CBFb binding (Kim et al., 2013). For comparison with this study, the
reported list of 155 genes with RUNX1-associated regulatory domains exhibiting Vif-dependent dif-
ferential gene expression in Jurkat T cells after 4 or 6 hr of PMA and PHA treatment was used.
Curated lists of ISGs have been previously described (Schoggins et al., 2014; Schoggins et al.,
2011). For comparison with this study, a list of 377 ISGs was compiled from these studies.
A recent study quantitated 7761 proteins in FACS-sorted T cells at a single time point 96 hr post-
infection with an R5-tropic, GFP-expressing Nef-deficient virus (Kuo et al., 2018). The comparator is
GFP negative rather than mock-infected cells (equivalent to SBP-DLNGFR negative cells in this
study), and the full dataset is not available. For comparison with this study, the published list of 1551
differentially expressed proteins (q < 0.05) was therefore used.
Flow cytometry
For primary T cells, CD3/CD28 Dynabeads were first removed using a DynaMag-2 magnet (Invitro-
gen). Typically 2e5 washed cells were incubated for 15 min in 100 mL PBS with the indicated fluoro-
chrome-conjugated antibody. All steps were performed on ice or at 4˚C and stained cells were fixed
in PBS/1% paraformaldehyde.
Immunoblotting
Cells were lysed in PBS/2% SDS supplemented with Halt Protease Inhibitor Cocktail (Thermo Scien-
tific) and Halt Phosphatase Inhibitor Cocktail (Thermo Scientific) for 10 min at RT. Benzonase (Sigma)
was included to reduce lysate viscosity. Post-nuclear supernatants were heated in Laemelli Loading
Buffer for 25 min at 50˚C, separated by SDS-PAGE and transferred to Immobilon-P membrane (Milli-
pore). Membranes were blocked in PBS/5% non-fat dried milk (Marvel)/0.2% Tween and probed
with the indicated primary antibody overnight at 4˚C. Reactive bands were visualised using HRP-con-
jugated secondary antibodies and SuperSignal West Pico or Dura chemiluminescent substrates
(Thermo Scientific). Typically 10–20 mg total protein was loaded per lane (Pierce BCA Protein Assay
kit).
Antibodies
Antibodies for immunoblot and flow cytometry are detailed in the Key resources table. The following
antibodies were obtained from the AIDS Reagent Program, Division of AIDS, NIAID, NIH: mouse
monoclonal anti-HIV-1 Vif (Simon et al., 1995) from Dr MH Malim, and mouse monoclonal anti-HIV-
1 Nef (Chang et al., 1998) from Dr JA Hoxie.
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